EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer

Diogo Assed Bastos, Andrey Soares, Fabio Augusto Barros Schutz, Eduardo Cronemberger, Murilo de Almeida Luz, Suelen Patricia Dos Santos Martins, David Queiroz Borges Muniz, Flavio Mavignier Cárcano, Oren Smaletz, Fábio Affonso Peixoto, Andrea Juliana Gomes, Felipe Melo Cruz und 9 weitere

JAMA Network Open · 2025

DOI: 10.1001/jamanetworkopen.2024.54253 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2025. Verfasst von Diogo Assed Bastos und 20 weiteren Autor:innen. Beteiligte Einrichtung: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Thiohydantoins, Abiraterone Acetate, Androgen Receptor Antagonists, Androgen Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The open-label randomized phase 2 LACOG0415 trial evaluated 3 treatment strategies for patients with advanced castration-sensitive prostate cancer (CSPC): androgen deprivation therapy (ADT) plus abiraterone acetate and prednisone (AAP), apalutamide (APA) alone, or APA plus AAP.

Objective

To investigate the association of ADT plus AAP, APA alone, or APA plus AAP with health-related quality of life (HRQOL) in patients with advanced CSPC in the LACOG0415 trial. Design, Setting, and Participants The LACOG0415 randomized clinical trial comprised 128 patients with advanced CSPC who were randomized (1:1:1) to 1 of 3 treatment arms from October 16, 2017, to April 23, 2019. Statistical analysis was conducted from March to September 2022.

Interventions

Patients were randomized (1:1:1) to 1 of 3 treatment arms: ADT plus AAP, APA alone, or APA plus AAP. Main Outcomes and Measures Health-related quality of life was evaluated using the Functional Assessment of Cancer Therapy–Prostate (FACT-P) questionnaire, including its subscales, completed at baseline and every 4 weeks until week 25. FACT-P scores range from 0 to 156, and higher scores indicate better HRQOL. Mean changes in score from baseline to week 25 were adjusted by baseline score and were calculated to evaluate whether there was a difference according to the treatment arm using a mixed-effect model for repeated measures. Time to deterioration was estimated by Kaplan-Meier curves and compared by stratified log-rank test. Analysis was performed on an intention-to-treat basis.

Results

A total of 128 patients with advanced CSPC were randomized to receive ADT plus AAP (n = 42; median age, 69.8 years [IQR, 58.9-71.6 years]), APA alone (n = 42; median age, 69.5 years [IQR, 59.8-72.6 years]), or APA plus AAP (n = 44; median age, 71.0 years [IQR, 63.0-72.3 years]). Metastatic disease was present in 95 patients (74.2%), high-risk biochemical recurrence disease in 22 (17.2%), and locally advanced disease in 11 (8.6%). There was no significant difference in baseline mean (SD) FACT-P total scores and subscales among the 3 treatment arms (FACT-P total score: ADT plus AAP arm, 118.5 [24.3]; APA alone arm, 116.1 [23.9]; AAP plus APA arm, 114.9 [18.1]; P = .69). Health-related quality of life was maintained during treatment period, and there were no statistically significant differences at 25 weeks in mean (SD) FACT-P total scores or subscales between treatment arms (FACT-P total score: ADT plus AAP arm, 122.3 [20.4]; APA alone arm, 119.5 [16.4]; AAP plus APA arm, 119.9 [20.3]). The APA alone and AAP plus APA arms were not associated with meaningful improvements in HRQOL compared with the ADT plus AAP arm, except in time to deterioration of the emotional well-being score, which was more favorable in the APA alone arm (reference arm: ADT plus AAP arm; APA alone arm: hazard ratio, 0.37 [0.15-0.85]; P = .02; ADT plus AAP arm: hazard ratio, 0.56 [0.26-1.19]; P = .13). Limitations include short follow-up period and the absence of other questionnaires to capture differences between therapies. Conclusions and Relevance In this prespecified secondary analysis of a randomized clinical trial of ADT plus AAP, APA alone, or APA plus AAP for patients with advanced CSPC, HRQOL was not statistically different between treatments with APA alone or APA plus AAP as compared with ADT plus AAP. Larger studies with longer follow-up and more specific questionnaires are needed to further evaluate HRQOL with these treatment strategies. Trial Registration ClinicalTrials.gov Identifier: NCT02867020

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiohydantoinsAbiraterone AcetateAndrogen Receptor AntagonistsAndrogen AntagonistsProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedQuality of LifeMiddle AgedPrednisone

Substanzen

apalutamideThiohydantoinsAbiraterone AcetatePrednisoneAndrogen Receptor AntagonistsAndrogen Antagonists

Autor:innen und Institutionen

  • Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
  • Department of Medical Oncology, Hospital Sírio-Libanês, São Paulo, Brazil.
  • Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Centro Paulista de Oncologia-Oncoclinicas, São Paulo, Brazil.
  • Department of Medical Oncology, Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
  • Centro Regional Integrado de Oncologia, Fortaleza, Brazil.

Zitieren

APA

Bastos, D. A., Soares, A., Schutz, F. A. B., Cronemberger, E., de Almeida Luz, M., Martins, S. P. D. S., Muniz, D. Q. B., Cárcano, F. M., Smaletz, O., Peixoto, F. A., Gomes, A. J., Cruz, F. M., Franke, F. A., Herchenhorn, D., Gidekel, R., Werutsky, G., Rebelatto, T. F., Gomes de Jesus, R., Souza, V. C., …, & Maluf, F. C. (2025). Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.54253

Vancouver

Bastos DA, Soares A, Schutz FAB, Cronemberger E, de Almeida Luz M, Martins SPDS, et al. Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer. JAMA Network Open. 2025. doi:10.1001/jamanetworkopen.2024.54253

BibTeX
@article{Bastos2025,
  author = {Bastos, Diogo Assed and Soares, Andrey and Schutz, Fabio Augusto Barros and Cronemberger, Eduardo and de Almeida Luz, Murilo and Martins, Suelen Patricia Dos Santos and Muniz, David Queiroz Borges and Cárcano, Flavio Mavignier and Smaletz, Oren and Peixoto, Fábio Affonso and Gomes, Andrea Juliana and Cruz, Felipe Melo and Franke, Fábio André and Herchenhorn, Daniel and Gidekel, Rosemarie and Werutsky, Gustavo and Rebelatto, Taiane Francieli and Gomes de Jesus, Rafaela and Souza, Vinicius Carrera and Fay, André Poisl and Maluf, Fernando Cotait},
  title = {Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2025},
  doi = {10.1001/jamanetworkopen.2024.54253}
}
Kostenlos starten →